down arrow

4D Molecular Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US35104E1001
USD
11.19
1.06 (10.46%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

10.5411.35

52 Week

2.2312.34
Valuation
Technical
Day's Volume

CASH

187.64 k

Shareholding (Mar 2025)

FII

20.20%

Held by 98 FIIs

DII

47.3%

Held by 31 DIIs

Promoter

7.02%

How big is 4D Molecular Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, 4D Molecular Therapeutics, Inc. has a market capitalization of 192.25 million, with net sales of 0.02 million and a net profit of -176.43 million over the latest four quarters. The company has shareholder's funds of 510.61 million and total assets of 560.38 million as of Dec 24.

Market Cap: <BR>As of Jun 18, 4D Molecular Therapeutics, Inc. has a market capitalization of 192.25 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, the company reported net sales of 0.02 million and a net profit of -176.43 million.<BR><BR>Balance Sheet Snapshot: <BR>As of Dec 24, the company has shareholder's funds amounting to 510.61 million and total assets of 560.38 million.

Read More

What does 4D Molecular Therapeutics, Inc. do?

22-Jun-2025

4D Molecular Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 and a net loss of $48 million as of March 2025. The company has a market cap of $192.25 million and key metrics indicate it is currently loss-making with no dividend yield.

Overview:<BR>4D Molecular Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -48 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 192.25 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.67 <BR>Return on Equity: -37.57% <BR>Price to Book: 0.41<BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is 4D Molecular Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of February 28, 2025, 4D Molecular Therapeutics, Inc. is assessed as overvalued and has deteriorated to a "does not qualify" valuation grade due to negative financial metrics, poor stock performance, and significant contrasts with peers.

As of 28 February 2025, the valuation grade for 4D Molecular Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently assessed as overvalued, given its negative financial metrics and lack of profitability. Key ratios include a Price to Book Value of 0.43, an EV to EBIT of 0.56, and an EV to EBITDA of 0.58, all of which suggest a lack of financial health.<BR><BR>In comparison to its peers, 4D Molecular Therapeutics, Inc. shows a stark contrast with Enliven Therapeutics, Inc. at an EV to EBITDA of -11.1774 and Avid Bioservices, Inc. at -118.0909, both indicating severe valuation challenges within the industry. The company's recent stock performance has been notably poor, with a year-to-date return of -32.32%, significantly underperforming the S&P 500's 2.44% return. This further reinforces the conclusion that the company is overvalued in its current state.

Read More

Is 4D Molecular Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, 4D Molecular Therapeutics, Inc. shows a mildly bullish trend supported by positive MACD and moving averages, despite mixed signals from Bollinger Bands and On-Balance Volume, while year-to-date performance outpaces the S&P 500 at 27.47%.

As of 25 August 2025, the technical trend for 4D Molecular Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The RSI shows a bullish signal on the monthly timeframe, although there is no signal on the weekly. The daily moving averages are bullish, supporting the overall positive stance. However, the Bollinger Bands indicate a mildly bearish trend on the monthly, and the KST is bearish on that same timeframe. The Dow Theory reflects a mildly bullish stance on the weekly but shows no trend on the monthly. The On-Balance Volume is mildly bearish on the weekly and shows no trend on the monthly.<BR><BR>In terms of multi-period returns, the stock has outperformed the S&P 500 year-to-date with a return of 27.47% compared to 12.22%, but it has significantly underperformed over the past year and three years, with returns of -57.79% and -19.77%, respectively. Overall, the current technical stance is mildly bullish, driven primarily by the bullish signals in MACD and moving averages.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 326 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.68

stock-summary
Return on Equity

-46.61%

stock-summary
Price to Book

0.77

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-55 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
72.95%
0%
72.95%
6 Months
189.15%
0%
189.15%
1 Year
58.05%
0%
58.05%
2 Years
-15.74%
0%
-15.74%
3 Years
-50.64%
0%
-50.64%
4 Years
-50.88%
0%
-50.88%
5 Years
0%
0%
0.0%

4D Molecular Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is 4D Molecular Therapeutics, Inc. technically bullish or bearish?

As of 25 August 2025, the technical trend for 4D Molecular Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The RSI shows a bullish signal on the monthly timeframe, although there is no signal on the weekly. The daily moving averages are bullish, supporting the overall positive stance. However, the Bollinger Bands indicate a mildly bearish trend on the monthly, and the KST is bearish on that same timeframe. The Dow Theory reflects a mildly bullish stance on the weekly but shows no trend on the monthly. The On-Balance Volume is mildly bearish on the weekly and shows no trend on the monthly. In terms of multi-period returns, the stock has outperformed the S&P 500 year-to-date with a return of 27.47% compared to 12.22%, but it has significantly underperformed over the past year and three years, with returns of -57.79% and -19...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-79.38%
EBIT Growth (5y)
-221.69%
EBIT to Interest (avg)
-108.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.67
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.43
EV to EBIT
0.56
EV to EBITDA
0.58
EV to Capital Employed
-0.74
EV to Sales
-114.25
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-37.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 47 Schemes (25.48%)

Foreign Institutions

Held by 98 Foreign Institutions (20.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -13.96% vs 3.42% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-57.60",
          "val2": "-51.90",
          "chgp": "-10.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-54.70",
          "val2": "-48.00",
          "chgp": "-13.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,963,733.30%",
          "val2": "-3,830,071.40%",
          "chgp": "-13,366.19%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 567.74% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -59.62% vs 6.23% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "20.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-181.10",
          "val2": "-107.10",
          "chgp": "-69.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-160.90",
          "val2": "-100.80",
          "chgp": "-59.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,076,783.80%",
          "val2": "-5,446.50%",
          "chgp": "-5,07,133.73%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-57.60
-51.90
-10.98%
Interest
0.00
0.00
Exceptional Items
-0.00
0.10
-100.00%
Consolidate Net Profit
-54.70
-48.00
-13.96%
Operating Profit Margin (Excl OI)
-3,963,733.30%
-3,830,071.40%
-13,366.19%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -13.96% vs 3.42% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
20.70
-100.00%
Operating Profit (PBDIT) excl Other Income
-181.10
-107.10
-69.09%
Interest
0.00
0.00
Exceptional Items
-0.00
-0.20
100.00%
Consolidate Net Profit
-160.90
-100.80
-59.62%
Operating Profit Margin (Excl OI)
-5,076,783.80%
-5,446.50%
-5,07,133.73%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 567.74% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -59.62% vs 6.23% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About 4D Molecular Therapeutics, Inc. stock-summary
stock-summary
4D Molecular Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."